Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da F. Gilardoni

Determinazione del perampanel plasmatico: confronto e cross-validazione tra due metodi in cromatografia liquida ad elevate prestazioni con rivelatore spettrofluorimetrico e con rivelatore a spettrometria di massa
Determination of perampanel in plasma samples: comparison and cross-validation between two HPLC methods utilizing two different detectors: spectrofluorimetric and mass spectrometry
<p>Determination of perampanel in plasma samples: comparison and cross-validation between two HPLC methods utilizing two different detectors: spectrofluorimetric and mass spectrometry. Perampanel (PMP) (2[2-oxo-1-phenyl-5-pyridin-2-y1-1,2 dihydropyridin-3-y1] benzonitrile hydrate) is a novel non-competitive selective antagonist of the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor. In this study, we compared two different methods for the quantification of perampanel in human plasma: a commercially available HPLC kit with fluorescent detector and a kit for determination of 18 different antiepileptic drugs (perampanel excluded) based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) used to implement the perampanel determination. LC-MS/MS method was fully validated according to available guidelines: calibration curves were linear across perampanel concentration range of 2,5-2,800 ng/mL with correlation coefficient &gt;0,99. Accuracy and precision results were in accordance with acceptance criteria (&plusmn;15%). Data collected from 95 patients, treated with perampanel as maintenance antiepileptic therapy, show a very strong correlation between the two methods. Perampanel plasma concentrations in patient samples at steady state, determined with the LC-MS/MS method, ranged from 35 to 985 ng/mL and are in line with previously reported data.</p>
Biochimica Clinica ; 42(3) 217-224
Contributi Scientifici - Scientific Paper
 
L’evoluzione dei criteri diagnostici per la sclerosi multipla non ha modificato la quota di pazienti con bande oligoclonali nel liquor
The evolution of diagnostic criteria for multiple sclerosis (MS) did not change the rate of patients displaying oligoclonal bands in the cerebrospinal fluid (CSF)
<p>The early diagnosis of MS, an inflammatory disease of the&nbsp;central nervous system, can be difficult. Although a specific laboratory test is lacking, the presence of CSF-restricted&nbsp;oligoclonal bands has been reported in the majority of patients (80-95%); as a consequence, this test has been&nbsp;included in the diagnostic criteria for many years. However, after each revision of the diagnostic criteria, the relevance&nbsp;of this test has progressively lost in importance, while magnetic resonance imaging has gained a central role. In the&nbsp;present study, two groups of MS patients diagnosed with McDonald (2001 and subsequent revisions) or with Poser&nbsp;(1983) criteria (176 and 82, respectively) were compared with regard to the frequency of the presence of oligoclonal&nbsp;bands in CSF. The same method for the oligoclonal pattern detection, based on isoelectric focusing followed by&nbsp;blotting and immunodetection of IgG, was used on both groups. Results showed that the rate of patients displaying&nbsp;CSF-restricted oligoclonal bands was 89.0% and 89.8% in the two groups, respectively (P=0.57). Our data suggest&nbsp;that the percentage of MS patients with CSF-restricted oligoclonal bands was unchanged and independent of the&nbsp;diagnostic criteria. Furthermore, the results suggest that the different MS diagnostic criteria considered (Poser vs.&nbsp;McDonald) identify patients with a similar immunological background.</p>
Biochimica Clinica ; 38(3) 213-217
Contributi scientifici - Scientific Papers